1,100 Hospitals Press HHS to Enforce 340B Pricing
In recent weeks several major drugmakers have stopped providing 340B pricings for safety-net hospitals. First, AstraZeneca announced it would stop offering discounts for 340B drugs beginning October 1. Then, Eli Lilly cut off discounts for the drugs, with a limited exception for insulin products. Merck, Sanofi and Novartis have also threatened to block access to discounts if hospitals don't provide them with claims data, which the letter says providers have no obligation to do under the law. The letter says that the actions of these manufacturers are "clear violations" of the 340B drug-pricing program and set a "dangerous precedent."